April 08, 2016
Authored and Edited by Elizabeth D. Ferrill; Jeff T. Watson
In MAG Aerospace Indus., Inc. v. B/E Aerospace, Inc., Nos. 15-1370, -1426 (Fed. Cir. Mar. 23, 2016), the Federal Circuit affirmed summary judgment of no invalidity based on assignor estoppel.
Assignor estoppel prevents the assignor of a patent, or one in privity with an assignor, from attacking the patent’s validity. Privity, like assignor estoppel, is determined by balancing the equities. In this case, one of the inventors, Mr. Pondelick, assigned the patents-in-suit to his former employer, who in turn assigned them to MAG. Mr. Pondelick later joined B/E.
At the district court, MAG asserted that assignor estoppel bars B/E from asserting the patents-in-suit are invalid, because Mr. Pondelick now works for B/E. In response, B/E argued that it should not be barred by assignor estoppel, because Mr. Pondelick joined B/E after the decision to develop the accused toilet was made and Mr. Pondelick had only a negligible financial interest in B/E.
The district court evaluated the parties’ arguments in light of the factors enumerated by the Federal Circuit in Shamrock Technologies, Inc. v. Medical Sterilization, Inc., 903 F.2d 789, 793 (Fed. Cir. 1990). Applying those factors, the district court found that (1) B/E availed itself of Mr. Pondelick’s knowledge to conduct the allegedly infringing activities, (2) Mr. Pondelick joined B/E to develop the accused toilets, and (3) he joined as the Director of Engineering and later became the VP and GM of the division responsible for manufacturing the accused toilets. Thus, the court found that Mr. Pondelick was in privity with B/E. Finding no abuse of discretion, the Federal Circuit affirmed.
Copyright © 2016 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in February 2024
April 16, 2024
Ad Law Buzz Blog
“Banning” a Banned Ingredients Claim: NAD’s Application (and Expansion) of the FTC’s Green Guides
March 18, 2024
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in January 2024
March 7, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.